Trondel C et al. CLEARED PODOCYTES AND NORMAL KIDNEY FUNCTION IN CLASSICAL FABRY MALES 15 YEARS AFTER START OF ENZYME REPLACEMENT THERAPY AT YOUNG AGE. Abstract MO 127. ERA-EDTA Congress 2021.
Najafian B et al. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.J ASN April 2020, 31 (4) 865-875
Schiffmann R et al. Enzyme Replacement Therapy in Fabry Disease. A Randomized Controlled Trial. JAMA. 2001;285(21):2743-2749
Ortiz A et al. Diagnosis and treatment of Fabry disease. Med Clin (Barc) 2017 Feb 9; 148(3):132-138.
Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, West ML. CFDI investigators. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab 2014;111:499–506.
Arends M et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet 2018; 55: 351-8
Ortiz A et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 2016; 53: 495-502